PHRI contribution to today’s tuberculosis diagnostics
TB – IGRA
PHRI developed M. tuberculosis-specific reagents utilized in Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection.
PHRI developed the molecular beacon technology that is used in the Cepheid Xpert MTB/RIF assay to diagnose active tuberculosis, including some forms of antibiotic-resistant tuberculosis.
PHRI developed reagents utilized in the most recent version of the assay detecting M. tuberculosis LAM (lipoarabinomannan) in the urine of people having active tuberculosis.